Buy or sell Vedanta Biosciences stock pre IPO via an EquityZen fund
Vedanta Biosciences Stock
Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome.
About Vedanta Biosciences Stock
Vedanta Biosciences was founded by PureTech and a team of world renowned experts in immunology and microbiology. Vedanta Biosciences is developing a class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. Vedanta Biosciences’ proprietary approach leverages foundational discoveries in the field of mucosal immunology to generate safe and potent treatments that restore intestinal homeostasis acting via mechanisms that are orthogonal to all existing drug classes. By modulating the microbiome with this class of drugs, we have the opportunity to treat a range of autoimmune and inflammatory diseases in potentially new ways and impact the lives of patients.
Chief Executive Officer
Co-Founder & Chair
Business Wire (press release) - May, 30 2018
IBD News Today - Dec, 15 2017
Business Wire (press release) - Dec, 7 2017
Business Wire (press release) - Nov, 3 2017
FierceBiotech - Aug, 11 2016